Clinical use of telaprevir: Stopping rules, predicting response, treatment length, and management of adverse effects

Keyphrases

• Adverse Effects 100%
• Anemia 50%
• Chronic Hepatitis C Virus Infection 25%
• Cirrhosis 25%
• Cirrhotic Patients 25%
• Clinical Application 100%
• Clinical Significance 25%
• Close Monitoring 25%
• Early Cessation 25%
• Fibrosis Stage 25%
• Futility Rules 25%
• Hepatitis C Virus RNA 50%
• Nave 25%
• Null Responder 25%
• Pegylated Interferon 75%
• Pegylated Interferon Therapy 25%
• Rapid Viral Response 50%
• Response Predictors 100%
• Ribavirin 100%
• Selecting Candidates 25%
• Short-term Treatment 25%
• Skin Rash 50%
• Stopping Rule 100%
• Sustained Viral Response 25%
• Telaprevir 100%
• Treatment Cessation 25%
• Treatment Duration 25%
• Treatment Length 100%
• Treatment Management 100%
• Triple Therapy 50%

Medicine and Dentistry

• Adverse Effect 100%
• Anemia 50%
• Chronic Hepatitis C 25%
• Clinical Significance 25%
• Combination Therapy 25%
• Exanthem 50%
• Fibrosis 25%
• Hepatitis C Virus 50%
• Liver Cirrhosis 25%
• Peginterferon 100%
• Recurrent Disease 25%
• Ribavirin 100%
• Telaprevir 100%
• Treatment Duration 25%
• Treatment Response 100%
• Virus RNA 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Anemia 50%
• Chronic Hepatitis C 25%
• Combination Therapy 25%
• Fibrosis 25%
• Hepatitis C Virus 50%
• Liver Cirrhosis 25%
• Peginterferon 100%
• Rash 50%
• Recurrent Disease 25%
• Ribavirin 100%
• Telaprevir 100%
• Virus RNA 50%